Osteomyelitis Therapeutics Market to Hit US$ 2.78 Billion by 2031 | Exclusive Report by Growth Plus Reports - Yahoo Finance

Growth Plus Reports

Growth Plus Reports

Newark, New Castle, USA, June 20, 2023 (GLOBE NEWSWIRE) -- According to the most recent study by Growth Plus Reports, the global osteomyelitis therapeutics market was valued at US$ 1.50 billion and is expected to rise at a revenue CAGR of 7.09% to reach US$ 2.78 billion by 2031.

The global market for osteomyelitis therapeutics was analyzed, and it is expected to rise significantly during the forecast period. Osteomyelitis, a bone infection, is an uncommon disease that may spread by various routes, including the bloodstream, bone exposure to a contaminated environment after surgery or injury, and other situations.

Request a Free Sample PDF: https://www.growthplusreports.com/inquiry/request-sample/osteomyelitis-therapeutics-market/8645

                                       Osteomyelitis Therapeutics Market Scope

Report Attribute

Details

Market size value in 2022

US$ 1.50 billion

Market Size Value in 2031

US$ 2.78 billion

Growth Rate

CAGR of 7.09% from 2023 to 2031

Base Year for Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Type, Patient Type, Treatment, Route of Administration, Distribution Channel, and Region

Regional scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Global Osteomyelitis Therapeutics Market: 

  • In June 2022, according to Amgen, the USFDA approved RIABNI, a Rituxan biosimilar, in combination with methotrexate for those with moderate to severely active Rheumatoid Arthritis.

  • In January 2022, Alkem Laboratories Ltd. introduced a revolutionary patented method for treating Diabetic Foot Ulcer (DFU). This solution would be based on cutting-edge 4D Bioprinting technology and would be used to treat chronic wounds that are deep and non-healing.

Key Takeaways: 

  • The large preference for minimally invasive surgical procedures drives market revenue growth.

  • The rising prevalence of bone disorders is boosting the demand for the treatment market.

  • Several advancements in therapies and increasing drug R&D are creating a strong product pipeline.

Market Drivers and Restraints: 

The global osteomyelitis therapeutics market revenue is driven by the increasing patient selection of non-invasive and minimally invasive surgical procedures. Furthermore, increasing R&D activities by pharmaceutical and biopharmaceutical companies to find novel medicines for the treatment of bone infections are likely to propel the market for bone infection treatment revenue growth forward.

However, the high cost of therapy, along with a scarcity of competent practitioners, restrains market revenue growth.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/osteomyelitis-therapeutics-market/8645

Market Segmentation: 

Segmentation By Type

Based on type, the global osteomyelitis therapeutics market is segmented into acute, chronic, and vertebral. Due to the rising prevalence of hematogenous (blood-borne) osteomyelitis, anaerobic osteomyelitis, and osteomyelitis pyogenic., the chronic osteomyelitis segment accounts for the largest market revenue share.

Segmentation By Patient Type

Based on patient type, the global osteomyelitis therapeutics market is segmented into adults and pediatrics. Due to various risk factors, such as diabetes, intravenous drug abuse, surgeries, and trauma, the adult segment accounts for the largest market revenue share.

Segmentation By Treatment

Based on treatment, the global osteomyelitis therapeutics market is segmented into antibiotics, antifungals, and analgesics. Due to the first line of treatment, the antibiotics segment accounts for the largest market revenue share.

Segmentation By Route of Administration

Based on the route of administration, the global osteomyelitis therapeutics market is segmented into parenteral, topical, and oral. Due to convenience, non-invasiveness, and being easily administered at home, the oral segment dominates the global market with its largest revenue share.

Segmentation By Distribution Channel

Based on distribution channels, the global osteomyelitis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Being the primary site of care for patients with osteomyelitis, the hospital pharmacy segment accounts for the largest revenue share in the global market.

Regional Growth Dynamics

Based on the region, the global osteomyelitis therapeutics market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. North America, with its largest revenue share, dominates the global market. Favorable payment regulations for osteomyelitis therapy bolster the healthcare system in North America.

Competitive Landscape

Following is a list of the top market players operating in the global market for osteomyelitis therapeutics:

Report Coverage 

Growth Plus Reports studied the global market for osteomyelitis therapeutics in-depth and analyzed the basic market characteristics, significant investment areas, analytics of regional growth, revenue forecast, competitive market players, mergers, and acquisitions.

Table of Content

  1. INTRODUCTION

    1. Market Ecosystem

    2. Timeline Under Consideration

      1. Historical Years – 2021

      2. Base Year – 2022

      3. Forecast Years – 2023 to 2031

    3. Currency Used in the Report

  2. RESEARCH METHODOLOGY 

    1. Research Approach

    2. Data Collection Methodology

    3. Data Sources

      1. Secondary Sources

      2. Primary Sources

    4. Market Estimation Approach

      1. Bottom Up

      2. Top Down

    5. Market Forecasting Model

    6. Limitations and Assumptions     

  3. PREMIUM INSIGHTS

    1. Current Market Trends (COVID-19 Perspective)

    2. Key Players & Competitive Positioning (2022)

    3. Regulatory Landscape

      1. U.S.

      2. Europe

      3. Japan

    4. Reimbursement Scenario

    5. Epidemiology and Patient Population

  4. MARKET DYNAMICS

    1. Drivers

    2. Restraints

    3. Opportunities

  5. GLOBAL OSTEOMYELITIS THERAPEUTICS MARKET- ANALYSIS & FORECAST, BY TYPE

    1. Acute

    2. Chronic

    3. Vertebral

  6. GLOBAL OSTEOMYELITIS THERAPEUTICS MARKET- ANALYSIS & FORECAST, BY PATIENT TYPE

    1. Adults

    2. Pediatric

  7. GLOBAL OSTEOMYELITIS THERAPEUTICS MARKET- ANALYSIS & FORECAST, BY TREATMENT

    1. Antibiotics

    2. Antifungals

    3. Analgesics

OSTEOMYELITIS THERAPEUTICS MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8645

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

  • Comprehensive quantitative and qualitative insights at segment and sub-segment level

  • Covid 19 impact trends and perspective

  • Granular insights at global/regional/country level

  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

  • Blanket coverage on competitive landscape

  • Winning imperatives

  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment

  • Pricing Intelligence

  • Customer Base Assessment

  • Investment & Initiatives Analysis

  • 'Business Profile' of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Cortisone Acetate Market by Indication (Rheumatic Diseases, Dermatologic Conditions), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Belladonna Alkaloids Market by Type (Atropine, Hyoscyamine), Application (Gastrointestinal Disorders, Respiratory Disorders, Overactive Bladder), Route of Administration (Oral, Topical), End User (Hospitals, Pharmaceutical Companies)-Global Outlook & Forecast 2023-2031

Calcium Homeostasis Drugs Market by Drug Class (Calcium Metabolism Modifiers, Parathyroid Hormone Analogs), Indication (Hypocalcemia, Hypercalcemia), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Mirvetuximab Soravtansine Market by Indication (Ovarian Cancer, Fallopian Tube Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: sales@growthplusreports.com 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today

Image
Scabies is a skin condition that occurs as the result of a mite known as Sarcoptes scabiei. The rash that results from scabies may appear similar to other skin conditions, such as psoriasis, eczema, or contact dermatitis. In this article, we look at what a scabies rash looks like. We also look at other rashes that are similar in appearance and their treatment options. Scabies is a common condition that occurs as the result of an infestation of a microscopic skin mite called Sarcoptes scabiei. The mites burrow under the skin, causing intense itching and a rash. The Centers for Disease Control and Prevention (CDC) describes the rash as pimple-like. On darker skin, the rash may be more difficult to see, but a person should be able to feel it. According to DermNet, a scabies rash is varied in appearance, and may appear as: pimple-like on the limbs and trunk widespread or coin-shaped small blisters scales lesions in the armpits, groin, navel, areolas, scrotum, buttocks, and along the penil...
Read more

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Image
Can I prevent a urinary tract infection? The following lifestyle changes can help prevent urinary tract infections: Practice good hygiene Practicing good hygiene is one of the best ways to help prevent UTIs. This is especially important if you have a vagina because your urethra is much shorter, and it's easier for E. coli to move from your rectum back into your body. Always wipe from front to back after a bowel movement (pooping) to avoid this. During your menstrual cycle, it's also a good idea to regularly change your period products, including pads and tampons. You should also avoid using any deodorants on your vagina. Drink plenty of fluids Drinking extra fluids — especially water — each day can help flush out bacteria from your urinary tract. Healthcare providers recommend drinking six to eight glasses of water daily. Change your peeing habits Peeing can play a big role in getting rid of bacteria from your body. Your pee is a waste product, and each time you empty your bla...
Read more

Symtuza: Uses, side effects, alternatives, and more - Medical News Today

Image
The Food and Drug Administration (FDA) approves prescription drugs such as Symtuza to treat certain conditions. Symtuza is FDA-approved to treat HIV-1 in adults and children who weigh at least 40 kilograms (kg), which is about 88 pounds (lb). It's approved for people who: have just been diagnosed with HIV and haven't started treatment yet, OR are changing from another HIV treatment and: have been on a stable antiretroviral regimen for at least 6 months (this means you haven't had any changes to your HIV drugs for at least 6 months) have a viral load (the amount of HIV in your blood) that's less than 50 copies per milliliter (mL) have HIV that doesn't have mutations (changes) that could make it resistant (less likely to respond) to darunavir or tenofovir (two of the active drugs in Symtuza) HIV explained HIV stands for human immunodeficiency virus. There are two forms of this virus, HIV-1 and HIV-2. HIV-1 is the most common form. HIV is transmitted through body fluid...
Read more